Zymeworks to Join Upcoming Investor Conferences

VANCOUVER, British Columbia – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotech firm focused on innovative biotherapeutics for hard-to-treat diseases, announced its participation in several investor conferences. The company will engage in one-on-one meetings and present at various events in June 2024.

Zymeworks will attend the Jefferies Global Healthcare Conference in New York, NY, with management engaging in one-on-one meetings on June 5-6 and a fireside chat scheduled for June 5 at 10:30 am ET. Additionally, they will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL, with one-on-one meetings and a presentation on June 12 at 2:00 pm ET. Lastly, they will join Citi’s 2024 European Healthcare Conference through virtual one-on-one meetings on June 20.

Zymeworks Inc. is dedicated to discovering, developing, and commercializing multifunctional biotherapeutics. Their mission is to significantly impact the lives of those affected by complex cancers and other diseases. The company's advanced therapeutic platforms and integrated drug development system enable precise engineering of unique antibody-based therapeutic candidates.

A notable achievement is the development of zanidatamab, a HER2-targeted bispecific antibody created using Zymeworks' proprietary Azymetric™ technology. Zanidatamab is undergoing evaluation in numerous global clinical trials as a potentially leading treatment for HER2-expressing cancers. The company has entered agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, giving them exclusive rights to develop and market zanidatamab in specific regions. A Biologics License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). Approval would mark it as the first HER2-targeted therapy for BTC in the U.S.

Zymeworks is also advancing a robust pipeline of product candidates, leveraging its expertise in antibody-drug conjugates and multispecific antibody therapeutics. These efforts target novel areas with significant unmet medical needs. Beyond its own pipeline, Zymeworks' therapeutic platforms are further strengthened through strategic partnerships with global biopharmaceutical firms.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!